Alzamend Neuro (ALZN)

The company’s most advanced platform is AL001, a patented ionic cocrystal formulation designed to deliver lithium through a combination of lithium, proline and salicylate. Lithium has a long history of medical use, particularly in mood disorders, but its therapeutic window and monitoring requirements can limit broader adoption. Alzamend is developing AL001 with the goal of preserving lithium’s potential benefits while improving its pharmacokinetic and tolerability profile. The programme is being studied for Alzheimer’s disease and has also been discussed in relation to psychiatric indications.

Alzamend’s second principal candidate is AL002, a cell-based therapeutic vaccine approach intended to stimulate the immune system against targets associated with Alzheimer’s pathology. The technology uses mutant-peptide sensitised cells to encourage an immune response that may help address disease-related processes in the brain.

ALZN is therefore a speculative biotechnology stock tied to high-risk, high-reward research in neurodegeneration and mental health. The company has no approved commercial product, and its long-term relevance will depend on whether its candidates can demonstrate meaningful safety and efficacy in controlled clinical trials.